Abstract 144P
Background
Paclitaxel is commonly used as second-line therapy in advanced gastric cancer (AGC). The decision to proceed with second-line chemotherapy and select a chemotherapy regimen may be critical in vulnerable AGC patients after progression with first-line chemotherapy. However, there are no predictive biomarkers to identify patients with AGC who benefit from paclitaxel-based chemotherapy.
Methods
This study included 288 patients with AGC receiving second-line paclitaxel-based chemotherapy between 2017 and 2022 from K-MASTER project, a nationwide, government-funded precision medicine initiative. The data included clinicogenomic factors: clinical (age [young-onset vs. others], sex, histology [intestinal vs. diffuse type], prior trastuzumab use, duration of first-line chemotherapy, etc.) and genomic factors (pathogenic or likely pathogenic variants). The data were randomly divided into training and test sets (0.8:0.2). Three machine-learning methods, including random forest (RF), logistic regression (LR), and artificial neural network with genetic embedding (ANN) models, were used to develop the prediction model and were validated in the test sets.
Results
The median age was 64 years (range, 25-91) and 65.6% were male. A total of 288 patients were divided into training (n=230) and test sets (n=58). There were no significant differences in baseline characteristics between training and test sets. In the training set, the AUC for prediction of progression-free survival (PFS) with paclitaxel-based chemotherapy was 0.51, 0.73, and 0.75 in RF, LR, and ANN models, respectively. In the test set, the Kaplan-Meier curves of PFS were separated according to the three models: 2.8 vs. 1.5 months (P=0.07) in RF, 2.3 vs. 6.5 months (P=0.07) in LR, and 2.1 vs. 7.6 months (P=0.02) in ANN models.
Conclusions
These machine-learning models integrated clinical and genomic factors and can guide the selection of patients with AGC with a greater likelihood of a benefit from second-line paclitaxel-based chemotherapy. Further studies are necessary to validate and update these models in independent datasets in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract